Navigation Links
Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital
Date:5/15/2009

, in that it can renew itself and differentiate to become some or all of the major specialized cell types of the particular tissue or organ in which it is found. The discovery of a number of conserved mechanisms from developmental biology and tissue repair has led to the identification of small molecules and biologics that can direct stem cell proliferation and function. Fate Therapeutics is developing these small molecule and biologic SCMs to modulate the activity of adult stem cells to stimulate healing or block cancer growth.

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem (iPS) cell technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. The Company's first therapeutic candidate is scheduled to enter clinical trials in early 2009 in hematopoietic stem cell support. In addition, Fate Therapeutics and Stemgent have formed an alliance - Catalyst - a collaborative program to provide its partners with first access to the most advanced induced pluripotent stem (iPS) cell technologies for drug discovery and development. Fate Therapeutics is headquartered in La Jolla, CA. For more information, please visit http://www.fatetherapeutics.com.

*****************

Fate Therapeutics along with Stemgent, Genzyme, Burrill & Company and WIRED Magazine, will be featured in a panel presentation entitled "Mastering Your (Cell) Fate: Stem Cells, iPSCs and the Future o
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... MINNEAPOLIS, MN , May 1, 2015 /PRNewswire/ - ... company producing sustainable chemicals, today announced that it has priced ... common stock at a price of $9.00 per share, ... option to purchase up to an additional 585,000 shares ... Company will be $35.1 million.  The offering is expected to ...
(Date:5/1/2015)... May 1, 2015 A new ... antithrombotic drugs will reach $22.4bn in 2019. That revenue ... Industry and Market Prospects 2015-2025 ,  published ... investigation is to provide forecasts and qualitative analyses of ... publisher and consultancy in London, UK ...
(Date:5/1/2015)... , May 1, 2015 ... Production Market by Product (Equipment, Consumables), by Type (Monoclonal, ... Diagnostic Labs, Research Institutes) - Analysis & Global ... studies the global Antibody Production Market for the ... is expected to reach $2.572 Billion by 2019 ...
(Date:4/30/2015)... WARREN, N.J. , April 30, 2015  Roka ... company focused on providing advanced testing solutions for the ... financial results for the first quarter of 2015 on ... markets. Roka Bioscience will also host a ... 7, 2015 to discuss its first quarter financial results. ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2
... Highlights Include Clinical Trial Updates, BETHESDA, Md., ... NWBT; OTC Bulletin Board: NWBO), (the,"Company or NWBT"), ... and Chief Executive Officer, will deliver a presentation ... vaccines for the,treatment of cancer, at the "Next ...
... (July 17, 2008) Researchers at the U.S. Department of ... have won two R&D 100 Awards for innovative fluid ... been awarded 101 R&D 100 Awards since the awards ... R&D 100 Award -- dubbed the "Oscars of innovation" ...
... Opens at The O2 This Autumn, - With ... exhibition to premiere at The O2, Body,Worlds & The ... von Hagens, go on sale today., (Photo: ... In partnership with the producers of the sensation ...
Cached Biology Technology:Northwest Biotherapeutics to Present at Next Generation Vaccine Conference 2Argonne researchers win 2 R&D 100 Awards 2Argonne researchers win 2 R&D 100 Awards 3Argonne researchers win 2 R&D 100 Awards 4Tickets for Brand New Exhibition 'Body Worlds & The Mirror of Time' on Sale 18 July 2Tickets for Brand New Exhibition 'Body Worlds & The Mirror of Time' on Sale 18 July 3
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/26/2015)... 26, 2015 The Granite Club, ... and athletic club, today announced it has implemented a ... of movement for members and staff, while restricting access ... process, we selected FST,s IMID Access system because it ... our members and staff, in addition to unparalleled security," ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... exists that people who lived or worked at Camp ... and 1985 were exposed to the industrial solvents tricholorethylene ... strong scientific evidence is not available to determine whether ... contaminants, says a new report from the National Research ...
... researchers have accelerated research into Multiple Sclerosis by discovering ... unravel the causes of MS and other autoimmune disease. ... in the prestigious journal Nature Genetics . ... mystery. This discovery reveals important new insights into the ...
... protein known to be overly active in breast cancer ... the structural composition of mammary tissue, potentially making it ... Lombardi Comprehensive Cancer Center at Georgetown University Medical Center ... in Washington, DC, the scientists report that the protein, ...
Cached Biology News:Scientific evidence of health problems from past contamination of drinking water at Camp Lejeune is limited and unlikely to be resolved with further study 2Scientific evidence of health problems from past contamination of drinking water at Camp Lejeune is limited and unlikely to be resolved with further study 3Scientific evidence of health problems from past contamination of drinking water at Camp Lejeune is limited and unlikely to be resolved with further study 4Aussie and Kiwi researchers make double MS genetic discovery 2Protein linked to change in tissue that surround and support breast tumors 2
... adapter allows the Thermo-Fast® ... AB-1000) PCR plates to ... ABI PRISM® 3700 capillary ... for information on the ...
... • Heat activated ,• Eliminates ... temperature ,• Excellent specificity allows extension ... secondary structures ,• Leaves an 'A' ... modified form of GeneChoice DNA Polymerase ...
... Form: buffered aqueous solution. ... from complex carbohydrates and glycoproteins. It is ... conditions where the pH must be neutral ... Unit Definition: One ...
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
Biology Products: